Search research articles
Contact Us
Filters
Showing results (1081-1090 of 1,120) with videos related to
Page
of 112
Sort By:
ACS Synthetic Biology
|
January 12, 2021
Mutation Maker, An Open Source Oligo Design Platform for Protein Engineering
Kaori Hiraga, Petr Mejzlik, Matej Marcisin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
HIV Infection and Survival Among Women With Cervical Cancer
Scott Dryden-Peterson, Memory Bvochora-Nsingo, Gita Suneja, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Heredity
|
July 30, 2009
The role of human demographic history in determining the distribution and frequency of transferase-deficient galactosaemia mutations
J M Flanagan, G McMahon, S H Brendan Chia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 15, 2014
Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership
Jason A Efstathiou, Memory Bvochora-Nsingo, David P Gierga, et al.
The Lancet. Haematology
|
October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 26, 2018
Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, et al.
Page
of 112
Search research articles
Search
Showing results (1081-1090 of 1,120) with videos related to
Sort By:
Page
of 112
ACS Synthetic Biology
|
January 12, 2021
Mutation Maker, An Open Source Oligo Design Platform for Protein Engineering
Kaori Hiraga, Petr Mejzlik, Matej Marcisin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2016
HIV Infection and Survival Among Women With Cervical Cancer
Scott Dryden-Peterson, Memory Bvochora-Nsingo, Gita Suneja, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Heredity
|
July 30, 2009
The role of human demographic history in determining the distribution and frequency of transferase-deficient galactosaemia mutations
J M Flanagan, G McMahon, S H Brendan Chia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 15, 2014
Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership
Jason A Efstathiou, Memory Bvochora-Nsingo, David P Gierga, et al.
The Lancet. Haematology
|
October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 26, 2018
Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, et al.
Page
of 112